<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-16</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-16</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>35</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>3</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
*   <strong>ç™Œç—‡å¼‚è´¨æ€§ä¸è°ƒæ§æœºåˆ¶</strong>ï¼šæ­ç¤ºäº†çŠ¬ç±»è‚›å‘¨è‚¿ç˜¤çš„è½¬å½•ç»„ç‰¹å¾ä¸ç™Œç—‡æ ‡å¿—ç‰©çš„å…³è”ï¼ˆGSE302161, GSE301538ï¼‰ï¼Œä»¥åŠè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„æ‹®æŠ—ä½œç”¨ï¼ˆGSE311260, GSE290623, GSE290622, GSE290619, GSE290618, GSE290617, GSE290616ï¼‰ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
-   <strong>è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«ç»†èƒ</strong>ï¼šç ”ç©¶äº†æ…¢æ€§å‹è¿«å¯¹å·¨å™¬ç»†èƒä¿ƒè‚¿ç˜¤è¡¨å‹çš„å½±å“ï¼ˆGSE304867ï¼‰ï¼Œä»¥åŠHIF-1Î±+ CD4 Tç»†èƒåœ¨è‚ºéƒ¨å…ç–«ç½‘ç»œä¸­çš„ä½œç”¨ï¼ˆGSE291539ï¼‰ã€‚<br />
-   <strong>ç»†èƒåˆ†åŒ–ä¸ç–¾ç—…å‘ç”Ÿ</strong>ï¼šæ¢ç´¢äº†è¡°è€è¿‡ç¨‹ä¸­ç ´éª¨ç»†èƒç”Ÿæˆè°ƒæ§å› å­ï¼ˆGSE221363ï¼‰ï¼Œä»¥åŠFTO/SOCS6-mâ¶Aè½´åœ¨è‚¥èƒ–ä¸ç‰¹åº”æ€§çš®ç‚ä¸­çš„ä½œç”¨ï¼ˆGSE312054ï¼‰ã€‚<br />
-   <strong>å¿ƒè„é‡å¡‘ä¸çº¤ç»´åŒ–</strong>ï¼šè§£æäº†Cthrc1åœ¨å¿ƒè‚Œæ¢—æ­»åå¿ƒå®¤é‡å¡‘ä¸­çš„å…³é”®ä½œç”¨ï¼ˆGSE267256, GSE261428ï¼‰ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
-   <strong>å•ç»†èƒå¤šç»„å­¦</strong>ï¼šç»“åˆDNAã€RNAå’Œè›‹ç™½è´¨è¿›è¡Œä¹³è…ºç™Œç»†èƒåˆ†æï¼ˆGSE291751ï¼‰ï¼›é€šè¿‡å•ç»†èƒå¤šç»„å­¦é‰´å®šè¡°è€ç›¸å…³ç ´éª¨ç»†èƒç”Ÿæˆè°ƒæ§å› å­ï¼ˆGSE221363ï¼‰ã€‚<br />
-   <strong>æ–°å‹RNAæµ‹åºæ–¹æ³•</strong>ï¼šå¼€å‘äº†ç”¨äºä¸‹ä¸€ä»£RNAæµ‹åºå’Œå°å‹RNAå®šé‡çš„æ— å‡èƒ¶æ–‡åº“åˆ¶å¤‡æŠ€æœ¯ï¼ˆGSE313501ï¼‰ã€‚</p>
<h3>ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
å›¾ç¥ç»ç½‘ç»œï¼ˆGNNsï¼‰ã€åµŒå…¥ï¼ˆEmbeddingsï¼‰å’ŒåŸºç¡€æ¨¡å‹ï¼ˆFoundation Modelsï¼‰æ­£åœ¨æ·±åˆ»æ”¹å˜ç©ºé—´æ•°æ®ç§‘å­¦é¢†åŸŸã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- åº”ç”¨GNNså¤„ç†ç©ºé—´ä¾èµ–æ€§å¼ºçš„æ•°æ®ï¼Œä¾‹å¦‚åœ°ç†ç©ºé—´æ•°æ®ã€‚<br />
- åˆ©ç”¨åµŒå…¥æŠ€æœ¯å­¦ä¹ ç©ºé—´å¯¹è±¡çš„ä½ç»´è¡¨ç¤ºï¼Œä»¥æ•æ‰å…¶å†…åœ¨ç‰¹å¾å’Œå…³ç³»ã€‚<br />
- æ¢ç´¢åŸºç¡€æ¨¡å‹åœ¨ç©ºé—´æ•°æ®åˆ†æä¸­çš„æ½œåŠ›ï¼Œå®ç°æ›´å¹¿æ³›çš„ä»»åŠ¡æ³›åŒ–ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- GNNsæä¾›äº†ä¸€ç§å¤„ç†å’Œåˆ†æå…·æœ‰å¤æ‚ç©ºé—´å…³ç³»çš„å›¾ç»“æ„æ•°æ®çš„å¼ºå¤§æ¡†æ¶ã€‚<br />
- åµŒå…¥æŠ€æœ¯ä¸ºç©ºé—´å¯¹è±¡æä¾›äº†ä¸€ç§æ–°çš„ã€æ›´å…·ä¿¡æ¯é‡çš„è¡¨ç¤ºæ–¹å¼ï¼Œä¾¿äºåç»­åˆ†æã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
è‚ é“èŒç¾¤åˆ†å­æ­ç¤ºèƒ½é‡ä»£è°¢æ–°æœºåˆ¶ï¼Œæœ‰æœ›é©æ–°è‚¥èƒ–ä¸ç³–å°¿ç—…æ²»ç–—ï¼›å¤©ç„¶åŒ–åˆç‰©Forskolinå¯¹æ”»å‡»æ€§ç™½è¡€ç—…å±•ç°æ˜¾è‘—ç–—æ•ˆã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚ é“èŒç¾¤ä»£è°¢ç‰©è°ƒæ§è‚è„èƒ½é‡åˆ©ç”¨<br />
- ForskolinæŠ‘åˆ¶ç™½è¡€ç—…ç»†èƒå¢æ®–ä¸å¢å¼ºå…ç–«æ¸…é™¤<br />
- æ–°å‹æˆåƒæŠ€æœ¯å®ç°è¡°è€ç»†èƒï¼ˆzombie cellsï¼‰åœ¨æ´»ä½“ç»„ç»‡ä¸­çš„å¯è§†åŒ–</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- é‰´å®šå‡ºè‚ é“èŒç¾¤è¡ç”Ÿçš„ã€å¯å½±å“å®¿ä¸»èƒ½é‡ä»£è°¢çš„å…³é”®åˆ†å­<br />
- å‘ç°Forskolinçš„åŒé‡æŠ—ç™Œæœºåˆ¶<br />
- å¼€å‘å‡ºå¯ç”¨äºå®šä½å’Œç ”ç©¶è¡°è€ç»†èƒçš„æ–°å‹æˆåƒæ–¹æ³•</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (31æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>GSE302161 è‚¿ç˜¤å°Šä¸¥è°±çš„æç«¯ï¼šä¸¤ç§å¸¸è§çŠ¬è‚›å‘¨è‚¿ç˜¤çš„è½¬å½•ç»„å›¾è°±ä¸ç™Œç—‡çš„æ ‡å¿—ç›¸ä¸€è‡´ [3' RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Alexander F Haake ; Alina K Loriani Fard ; Vladimir M Jovanovic ; Michael Hummel ; Sandro Andreotti ; Achim D GruberSeries Type : Expression profiling by high throughput sequencingOrganism : Canis lupus familiarisThe hallmarks of cancer describe stepwise changes in cellular functions and molecular pathways of tumour cells that undergo malignant progression. Although 14 hallmarks have been proposed, their manifestation at the molecular level across different tumour types remains incompletely understood. Here, we hypothesised that hallmark-associated transcriptomic signatures reflect the contrasting biological behaviours of a pair of a benign and a highly malignant tumour. To this end, we compared the two most common canine perianal tumours, the highly malignant apocrine gland anal sac adenocarcinoma (AGASAC) and the benign hepatoid gland adenoma (HGA). Spontaneous tumours were analysed using 3' RNA-Seq (AGASAC n = 15, HGA n = 10) and a direct mRNA hybridisation panel (AGASAC n = 33, HGA n = 12). Large transcriptomic differences were observed in both the number of differentially expressed genes and enriched pathways. Hallmarks such as â€œsustaining proliferative signallingâ€, â€œevading growth suppressorsâ€, and â€œtumour-promoting inflammationâ€ were prominent in AGASACs, while HGAs showed enrichment for â€œderegulating cellular metabolismâ€ and â€œresisting cell deathâ€. Surprisingly, some transcriptomic differences were not as clearly differentiating or evident, such as â€œactivating invasion and metastasisâ€ or â€œinducing or accessing vasculatureâ€. Additionally, our data point towards a subgrouping of AGASACs associated with the inflammatory landscape, supporting the notion that it is a promising candidate for immune checkpoint inhibitor therapy. Overall, the transcriptomes of these two extremes on the tumour dignity spectrum clearly contrasted each other in select aspects of the hallmarks. Still, their malignant or benign behaviours could not generally be mirrored on the mRNA level.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302161" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>GSE312117 RNA-seq åˆ†æäº†ä½“å¤–åŸ¹å…»çš„é‡ç”Ÿå‹ E-mu-Myc ç»†èƒå’Œä½“å†…ç”¨ Vehicle å’Œ ASNase å¤„ç†çš„ E-mu-Myc ç»†èƒè¡ç”Ÿçš„ B ç»†èƒæ·‹å·´ç˜¤ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šlymphomaã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Johanna Chiche ; Nicolas Nottet ; Jean-Ehrland RicciSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis dataset contains RNA-seq profiles of wild-type E-mu-Myc-lymphoma cells in two experimental contexts. First, E-mu-Myc-cells isolated from 12 individual transgenic EÂµ-MycTg/+ mouse were cultured in vitro under standard growth conditions. Second, RNA-seq was also performed on bulk B-cell lymphomas of wild-type C57BL/6 mice engrafted with E-mu-Myc-#506 cells and treated with either Vehicle or L-asparaginase (ASNase) until disease endpoint. This dataset enables the comparison of transcriptional programs between in vitroâ€“cultured E-mu-Myc-cells. It also evaluates the transcriptional responses to ASNase treatment in vivo in established B-cell lymphomas grown in C57BL/6 mice (n=1 BCL/group).<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312117" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>GSE311260 ä¸åŒè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„ç›¸ååŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Huang ; Dan Feng ; Sneha Mitra ; Emma S Andretta ; Nima B Hooshdaran ; Aazam P Ghelani ; Eric Y Wang ; Joe N Frost ; Victoria Lawless ; Aparna Vancheswaran ; Qingwen Jiang ; Christina S Leslie ; Alexander Y RudenskySeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusRegulatory T (Treg) cells are considered major contributors to the growth of solid organ tumors, with the notable exception of colorectal cancer (CRC), despite the documented abundance of Treg cells in CRC. Here, we demonstrate that IL-10âº and IL-10â» Treg cells constitute two distinct subsets with opposing functions: IL-10âº Treg cells counteract, while IL-10â» Treg cells promote, the growth of genetically engineered CRC tumors. Our findings suggest that the tumor-suppressive function of IL-10âº Treg cells is mediated by their suppression of effector CD4âº T cell production of IL-17, a cytokine that directly stimulates CRC tumor cell proliferation. Consistently, IL-10âº Treg cells were more abundant in both mouse and human CRC tumors than in tumor-adjacent normal colon tissue, whereas IL-10â» Treg cells exhibited the opposite distribution. Furthermore, gene expression signatures associated with IL-10âº and IL-10â» Treg cells correlated with better and worse disease prognoses in human CRC, respectively. This functional dichotomy between Treg subsets provides a rationale for therapeutic strategies aimed at selectively targeting pro-tumoral Treg cells while preserving their anti-tumoral counterparts across various barrier tissue cancers that harbor both subsets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311260" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE304867 æ…¢æ€§å‹è¿«é‡ç°äº†ä¸ä¿ƒè‚¿ç˜¤è¡¨å‹ç›¸å…³çš„å·¨å™¬ç»†èƒçš„è½¬å½•ã€ä»£è°¢å’ŒåŠŸèƒ½çŠ¶æ€å˜åŒ–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€metabolic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Alice A Burchett ; Hao Chen ; Julian Najera ; Sc ott Howard ; Meenal DattaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusMacrophages comprise a significant portion of the glioblastoma tumor microenvironment and are essential in promoting immunosuppression and tumor progression. Solid tumors such as glioblastoma generate solid stress as they expand, creating a compressive microenvironment for mechanosensitive immune cells including macrophages. Macrophages are known to respond to various mechanical stimuli but have not yet been studied in the context of chronic compression observed in growing tumors. Here, we used a custom in vitro compression system to elucidate the effects of compressive solid stress on murine macrophages. We found that macrophages have significant morphological, transcriptional, metabolic, and functional responses to compression. These changes corresponded to both canonical pro- and anti-inflammatory macrophage states. The gene expression signatures of compressed macrophages more closely resembled those of glioma-associated macrophages known to be associated with worse patient outcomes. These results indicate that compression alone, independent from tumor cell-derived biochemical factors, may contribute to the pathological tumor-associated macrophage phenotype. This could represent a vicious cycle of tumor immunomechanics and mechano-immunology. Targeting solid stress in tumors or the response to solid stress by macrophages may interrupt this feedback loop to help normalize the tumor immune microenvironment and improve glioblastoma response to immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304867" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE291751 Profling of breast cancer cells using single-cell triomics analysis of DNA, RNA, and proteins with Tapestri chemistry</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Emma Jonasson ; Stefan Filges ; Anna Gustafsson ; Anders StÃ¥hlbergSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensCancer displays large heterogeneity both between and within tumors where intratumor heterogeneity can occur at genetical, transcriptional and translational level. The variability results in tumor cell subpopulations with distinct molecular and cellular characteristics, some of which can have therapy-resistant properties. To date it has been experimentally challenging to study tumor cell heterogeneity. Here, we present a single-cell triomics approach to assess DNA, RNA and protein simultaneously in thousands of single cells using microfluidics. First, we profiled two breast cancer cell lines, MCF7 and T-47D, cultured in monolayer with and without 5-fluorouracil treatment. Next, we generated cell-free patient-derived scaffolds (PDS) that we repopulated with MCF7 cells for 21 days. This experimental model system mimics in vivo tumor cell growth and is suitable for drug testing, such as chemotherapies. We profiled individual MCF7 cells cultured in different PDSs with and without 5-fluorouracil treatment using triomics. Our approach and data demonstrate that single-cell triomics is feasible, which opens up new means to decipher tumor heterogeneity at different layers.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291751" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE290623 ä¸åŒè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„ç›¸ååŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Huang ; Dan Feng ; Sneha Mitra ; Emma S Andretta ; Nima B Hooshdaran ; Aazam P Ghelani ; Eric Y Wang ; Joe N Frost ; Victoria R Lawless ; Aparna Vancheswaran ; Qingwen Jiang ; Cheryl Mai ; Karuna Ganesh ; Christina S Leslie ; Alexander Y RudenskySeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencing ; OtherOrganism : Homo sapiens ; Mus musculusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290623" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE290622 ä¸åŒè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„ç›¸ååŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Huang ; Dan Feng ; Sneha Mitra ; Emma S Andretta ; Nima B Hooshdaran ; Aazam P Ghelani ; Eric Y Wang ; Joe N Frost ; Victoria Lawless ; Aparna Vancheswaran ; Qingwen Jiang ; Christina S Leslie ; Alexander Y RudenskySeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensRegulatory T (Treg) cells are considered major contributors to the growth of solid organ tumors, with the notable exception of colorectal cancer (CRC), despite the documented abundance of Treg cells in CRC. Here, we demonstrate that IL-10âº and IL-10â» Treg cells constitute two distinct subsets with opposing functions: IL-10âº Treg cells counteract, while IL-10â» Treg cells promote, the growth of genetically engineered CRC tumors. Our findings suggest that the tumor-suppressive function of IL-10âº Treg cells is mediated by their suppression of effector CD4âº T cell production of IL-17, a cytokine that directly stimulates CRC tumor cell proliferation. Consistently, IL-10âº Treg cells were more abundant in both mouse and human CRC tumors than in tumor-adjacent normal colon tissue, whereas IL-10â» Treg cells exhibited the opposite distribution. Furthermore, gene expression signatures associated with IL-10âº and IL-10â» Treg cells correlated with better and worse disease prognoses in human CRC, respectively. This functional dichotomy between Treg subsets provides a rationale for therapeutic strategies aimed at selectively targeting pro-tumoral Treg cells while preserving their anti-tumoral counterparts across various barrier tissue cancers that harbor both subsets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290622" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE290619 ä¸åŒè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„ç›¸ååŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Huang ; Dan Feng ; Sneha Mitra ; Emma S Andretta ; Nima B Hooshdaran ; Aazam P Ghelani ; Eric Y Wang ; Joe N Frost ; Victoria Lawless ; Aparna Vancheswaran ; Qingwen Jiang ; Christina S Leslie ; Alexander Y RudenskySeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusRegulatory T (Treg) cells are considered major contributors to the growth of solid organ tumors, with the notable exception of colorectal cancer (CRC), despite the documented abundance of Treg cells in CRC. Here, we demonstrate that IL-10âº and IL-10â» Treg cells constitute two distinct subsets with opposing functions: IL-10âº Treg cells counteract, while IL-10â» Treg cells promote, the growth of genetically engineered CRC tumors. Our findings suggest that the tumor-suppressive function of IL-10âº Treg cells is mediated by their suppression of effector CD4âº T cell production of IL-17, a cytokine that directly stimulates CRC tumor cell proliferation. Consistently, IL-10âº Treg cells were more abundant in both mouse and human CRC tumors than in tumor-adjacent normal colon tissue, whereas IL-10â» Treg cells exhibited the opposite distribution. Furthermore, gene expression signatures associated with IL-10âº and IL-10â» Treg cells correlated with better and worse disease prognoses in human CRC, respectively. This functional dichotomy between Treg subsets provides a rationale for therapeutic strategies aimed at selectively targeting pro-tumoral Treg cells while preserving their anti-tumoral counterparts across various barrier tissue cancers that harbor both subsets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290619" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE290618 ä¸åŒè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„ç›¸ååŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Huang ; Dan Feng ; Sneha Mitra ; Emma S Andretta ; Nima B Hooshdaran ; Aazam P Ghelani ; Eric Y Wang ; Joe N Frost ; Victoria Lawless ; Aparna Vancheswaran ; Qingwen Jiang ; Christina S Leslie ; Alexander Y RudenskySeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusRegulatory T (Treg) cells are considered major contributors to the growth of solid organ tumors, with the notable exception of colorectal cancer (CRC), despite the documented abundance of Treg cells in CRC. Here, we demonstrate that IL-10âº and IL-10â» Treg cells constitute two distinct subsets with opposing functions: IL-10âº Treg cells counteract, while IL-10â» Treg cells promote, the growth of genetically engineered CRC tumors. Our findings suggest that the tumor-suppressive function of IL-10âº Treg cells is mediated by their suppression of effector CD4âº T cell production of IL-17, a cytokine that directly stimulates CRC tumor cell proliferation. Consistently, IL-10âº Treg cells were more abundant in both mouse and human CRC tumors than in tumor-adjacent normal colon tissue, whereas IL-10â» Treg cells exhibited the opposite distribution. Furthermore, gene expression signatures associated with IL-10âº and IL-10â» Treg cells correlated with better and worse disease prognoses in human CRC, respectively. This functional dichotomy between Treg subsets provides a rationale for therapeutic strategies aimed at selectively targeting pro-tumoral Treg cells while preserving their anti-tumoral counterparts across various barrier tissue cancers that harbor both subsets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290618" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE290617 ä¸åŒè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„ç›¸ååŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€T cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Huang ; Dan Feng ; Sneha Mitra ; Emma S Andretta ; Nima B Hooshdaran ; Aazam P Ghelani ; Eric Y Wang ; Joe N Frost ; Victoria Lawless ; Aparna Vancheswaran ; Qingwen Jiang ; Christina S Leslie ; Alexander Y RudenskySeries Type : Other ; Expression profiling by high throughput sequencingOrganism : Mus musculusRegulatory T (Treg) cells are considered major contributors to the growth of solid organ tumors, with the notable exception of colorectal cancer (CRC), despite the documented abundance of Treg cells in CRC. Here, we demonstrate that IL-10âº and IL-10â» Treg cells constitute two distinct subsets with opposing functions: IL-10âº Treg cells counteract, while IL-10â» Treg cells promote, the growth of genetically engineered CRC tumors. Our findings suggest that the tumor-suppressive function of IL-10âº Treg cells is mediated by their suppression of effector CD4âº T cell production of IL-17, a cytokine that directly stimulates CRC tumor cell proliferation. Consistently, IL-10âº Treg cells were more abundant in both mouse and human CRC tumors than in tumor-adjacent normal colon tissue, whereas IL-10â» Treg cells exhibited the opposite distribution. Furthermore, gene expression signatures associated with IL-10âº and IL-10â» Treg cells correlated with better and worse disease prognoses in human CRC, respectively. This functional dichotomy between Treg subsets provides a rationale for therapeutic strategies aimed at selectively targeting pro-tumoral Treg cells while preserving their anti-tumoral counterparts across various barrier tissue cancers that harbor both subsets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290617" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 21 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡ (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>æˆ¿é—´é‡Œçš„å¤§è±¡ï¼šç©ºé—´æ•°æ®ç§‘å­¦ä¸­çš„å›¾ç¥ç»ç½‘ç»œã€åµŒå…¥å’ŒåŸºç¡€æ¨¡å‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatial<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSlides: https://jakubnowosad.com/agforum2025 This presentation covered three interconnected deep learning concepts appearing in spatial data science work. Graph Neural Networks (GNNs) are a deep learning architecture that represents spatial dat... Continue reading: Elephant(s) in the room: Graph neural networks, embeddings, and foundation models in spatial data science<br />
- ğŸ”— <a href="https://www.r-bloggers.com/2025/12/elephants-in-the-room-graph-neural-networks-embeddings-and-foundation-models-in-spatial-data-science/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>å“ˆä½›å¤§å­¦è‚ é“ç ”ç©¶æˆæœæˆ–å°†æ”¹å˜æˆ‘ä»¬æ²»ç–—è‚¥èƒ–ç—‡å’Œç³–å°¿ç—…çš„æ–¹å¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgutã€regex:gut(-?microbiome)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists found that certain molecules made by gut bacteria travel to the liver and help control how the body uses energy. These molecules change depending on diet, genetics, and shifts in the microbiome. Some even improved insulin response in liver cells when tested in the lab. The findings could open the door to new ways of preventing or managing obesity and diabetes.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251214100926.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>å¤©ç„¶åŒ–åˆç‰©å¯æ˜¾è‘—å¢å¼ºå¯¹ä¾µè¢­æ€§ç™½è¡€ç—…çš„æ²»ç–—æ•ˆæœ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemia<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šForskolin, a plant-derived compound, shows surprising potential against one of the most aggressive forms of leukemia. Researchers discovered that it not only stops cancer cells from growing but also makes them far more vulnerable to chemotherapy by preventing them from pumping out the drugs meant to kill them. Experts say this dual action could help create safer, more powerful AML treatments with fewer harsh side effects.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251213032619.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ä¸€ä½ç ”ç©¶ç”Ÿçš„å¥‡æ€å¦™æƒ³å¼•å‘äº†è¡°è€ç ”ç©¶çš„é‡å¤§çªç ´ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šaging<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSenescent â€œzombieâ€ cells are linked to aging and multiple diseases, but spotting them in living tissue has been notoriously difficult. Researchers at Mayo Clinic have now taken an inventive leap by using aptamersâ€”tiny, shape-shifting DNA moleculesâ€”to selectively tag these elusive cells. The project began as an offbeat conversation between two graduate students and quickly evolved into a collaborative, cross-lab effort that uncovered aptamers capable of binding to unique surface proteins on senescent cells.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251213032625.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>11</td>
</tr>
<tr>
<td>T cell</td>
<td>7</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>6</td>
</tr>
<tr>
<td>aging</td>
<td>3</td>
</tr>
<tr>
<td>cardiac</td>
<td>3</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>single-cell</td>
<td>2</td>
</tr>
<tr>
<td>epigenetic</td>
<td>1</td>
</tr>
<tr>
<td>leukemia</td>
<td>1</td>
</tr>
<tr>
<td>gut</td>
<td>1</td>
</tr>
<tr>
<td>regex:gut(-?microbiome)?</td>
<td>1</td>
</tr>
<tr>
<td>spatial</td>
<td>1</td>
</tr>
<tr>
<td>sequencing</td>
<td>1</td>
</tr>
<tr>
<td>resistance</td>
<td>1</td>
</tr>
<tr>
<td>lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>kinase</td>
<td>1</td>
</tr>
<tr>
<td>tumor</td>
<td>1</td>
</tr>
<tr>
<td>proteomics</td>
<td>1</td>
</tr>
<tr>
<td>RNAseq</td>
<td>1</td>
</tr>
<tr>
<td>immune</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (21æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290616" target="_blank" rel="noopener noreferrer">GSE290616 ä¸åŒè°ƒèŠ‚æ€§Tç»†èƒäºšç¾¤åœ¨ç»“ç›´è‚ ç™Œä¸­çš„ç›¸ååŠŸèƒ½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267256" target="_blank" rel="noopener noreferrer">GSE267256 æ‰¹é‡ RNA-seq åˆ†ææ­ç¤ºäº†èƒ¶åŸè›‹ç™½ä¸‰èºæ—‹é‡å¤åºåˆ—åŒ…å«è›‹ç™½ 1 (Cthrc1) å¿ƒè„æˆçº¤ç»´ç»†èƒåœ¨å¿ƒè‚Œæ¢—æ­»åå¿ƒå®¤é‡å¡‘ä¸­çš„å…³é”®ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261428" target="_blank" rel="noopener noreferrer">GSE261428 å•ç»†èƒ RNA æµ‹åºåˆ†ææ­ç¤ºäº†èƒ¶åŸè›‹ç™½ä¸‰èºæ—‹é‡å¤åºåˆ—åŒ…å«è›‹ç™½ 1 (Cthrc1) å¿ƒè„æˆçº¤ç»´ç»†èƒåœ¨å¿ƒè‚Œæ¢—æ­»åå¿ƒå®¤é‡å¡‘ä¸­çš„å…³é”®ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221363" target="_blank" rel="noopener noreferrer">GSE221363 å•ç»†èƒå¤šç»„å­¦ç ”ç©¶æ­ç¤ºäº†è¡°è€è¿‡ç¨‹ä¸­ç ´éª¨ç»†èƒç”Ÿæˆå¢åŠ æ‰€éœ€çš„æ–°å‹è°ƒæ§å› å­</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312054" target="_blank" rel="noopener noreferrer">GSE312054 è„‚è‚ªé‡å’Œè‚¥èƒ–ç›¸å…³ï¼ˆFTOï¼‰/SOCS6-mâ¶Aè½´è¡¨è§‚é—ä¼ ä¿®é¥°é€šè¿‡è°ƒèŠ‚è§’è´¨å½¢æˆç»†èƒåŠŸèƒ½å°†è‚¥èƒ–ä¸ç‰¹åº”æ€§çš®ç‚è”ç³»èµ·æ¥</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313501" target="_blank" rel="noopener noreferrer">GSE313501 ç”¨äºä¸‹ä¸€ä»£ RNA æµ‹åºå’Œå° RNA å®šé‡åˆ†æçš„æ— å‡èƒ¶æ–‡åº“åˆ¶å¤‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313494" target="_blank" rel="noopener noreferrer">GSE313494 Heterogeneity of senescent cells underlies resistance to ABT263 and ARV825</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309178" target="_blank" rel="noopener noreferrer">GSE309178 ä¿å®ˆå°è›‹ç™½ SniP3 å‚ä¸è“è—»çš„æ°®èƒè¿«ååº”å’Œä»£è°¢è°ƒæ§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309005" target="_blank" rel="noopener noreferrer">GSE309005 CDK8/19æ¿€é…¶æŠ‘åˆ¶å‰‚SNX 631å¯¹OV90äº²æœ¬å’ŒæŠ—å¤±å·¢å‡‹äº¡åŒæºç³»çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301538" target="_blank" rel="noopener noreferrer">GSE301538 è‰¯æ¶æ€§è‚¿ç˜¤è°±çš„æç«¯æƒ…å†µï¼šåŸºäºç™Œç—‡ç‰¹å¾çš„ä¸¤ç§å¸¸è§çŠ¬è‚›å‘¨è‚¿ç˜¤ä¹‹é—´ä¸åŒçš„è½¬å½•ç»„å›¾è°± [nCounterÂ®]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295151" target="_blank" rel="noopener noreferrer">GSE295151 çº¿ç²’ä½“è›‹ç™½é…¶ Afg3l2 é€šè¿‡ Mmadhc è°ƒèŠ‚å°é¼ é€ è¡€å¹²ç»†èƒå’Œç¥–ç»†èƒçš„ç¨³æ€ [è›‹ç™½è´¨ç»„å­¦]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295143" target="_blank" rel="noopener noreferrer">GSE295143 çº¿ç²’ä½“è›‹ç™½é…¶ Afg3l2 é€šè¿‡ Mmadhc è°ƒèŠ‚å°é¼ é€ è¡€å¹²ç»†èƒå’Œç¥–ç»†èƒçš„ç¨³æ€ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293224" target="_blank" rel="noopener noreferrer">GSE293224 å¯¹å¥åº·å¯¹ç…§ç»„å’Œç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®æ‚£è€…çš„äººç±»ä¸­æ€§ç²’ç»†èƒè¿›è¡Œ RNA æµ‹åºåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291539" target="_blank" rel="noopener noreferrer">GSE291539 HIF-1Î±+ CD4 T ç»†èƒåè°ƒè‚ºéƒ¨ç»„ç»‡é©»ç•™å…ç–«ç»†èƒç½‘ç»œ [Xenium]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291386" target="_blank" rel="noopener noreferrer">GSE291386 HSPC è¡ç”Ÿçº¢ç»†èƒåˆ†åŒ–çš„æŸ“è‰²è´¨å¯åŠæ€§åˆ†æ â€‹â€‹[ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288110" target="_blank" rel="noopener noreferrer">GSE288110 TBP è°ƒæ§å°é¼ æ—©æœŸèƒšèƒä¸­è½¬åº§å…ƒä»¶çš„è¡¨è¾¾ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282321" target="_blank" rel="noopener noreferrer">GSE282321 KDM3A å‚¬åŒ–ç»„è›‹ç™½ H3K9 ä¸Šç¾Ÿä¹™é…°èµ–æ°¨é…¸çš„å½¢æˆ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE265828" target="_blank" rel="noopener noreferrer">GSE265828 æ­ç¤ºå¿ƒè‚Œæ¢—æ­»åä¿®å¤æ€§å¿ƒè„æˆçº¤ç»´ç»†èƒçš„åˆ†å­æ¿€æ´»æœºåˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255766" target="_blank" rel="noopener noreferrer">GSE255766 MCF-7 ESR1 è¯ç‰©ååº” scRNA</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE247440" target="_blank" rel="noopener noreferrer">GSE247440 å°é¼ å™¨å®˜è¡°è€åŸºå› è¡¨è¾¾ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65632" target="_blank" rel="noopener noreferrer">GSE65632 ç”²æ°¨è¶å‘¤å­µè‚²HT29äººç»“è‚ ç™Œç»†èƒåŸºå› è¡¨è¾¾çš„æ—¶é—´è¿›ç¨‹åˆ†æ</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-15 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>